Etofibrate
CAS: 31637-97-5
Ref. 3D-FE23196
25mg | Descatalogado | ||
50mg | Descatalogado | ||
100mg | Descatalogado | ||
250mg | Descatalogado | ||
500mg | Descatalogado |
Información del producto
- 3-Pyridinecarboxylic acid 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl esterEthofibrateLipo-merz
- 2-{[2-(4-Chlorophenoxy)-2-Methylpropanoyl]Oxy}Ethyl Pyridine-3-Carboxylate
- 2-{[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxy}ethyl nicotinate
- 250-743-1
- 3-Pyridinecarboxylic Acid, 2-[2-(4-Chlorophenoxy)-2-Methyl-1-Oxopropoxy]Ethyl Ester
- Ethofibrate
- Ethylene Glycol 1-[2-(p-Chlorophenoxy)-2-methylpropionate]-2-nicotinate
- Lipo-Merz
- Nicotinic Acid 2-Hydroxyethyl Ester 2-(p-Chlorophenoxy)-2-methylpropionate (Ester)
- Tricerol
- Ver más sinónimos
- a-[(p-Chlorophenoxy)isobutyroyl]-b-(nicotinoyl)glycol
Etofibrate is a pyrazole-containing compound that inhibits the enzyme DPP-IV, which is involved in the degradation of glucagon, thereby increasing the level of circulating glucagon. Etofibrate has been shown to be useful for treating people with bowel disease and hypoglycemic effect. It has also been shown to have anti-inflammatory effects. The mechanism of action is not well understood, but it may be due to its ability to inhibit lipid synthesis or decrease cholesterol levels. Etofibrate can be used as a cholesterol-lowering agent in patients with type 2 diabetes and atherosclerosis. It also has an immunomodulatory effect on infectious diseases such as tuberculosis by inhibiting the growth of bacteria and reducing inflammation.